UNIVERSIDAD NACIONAL DEL SUR

Their core work

Universidad Nacional del Sur is a major Argentine public research university in Bahia Blanca, participating in H2020 as a non-EU third-party partner through MSCA-RISE staff exchange programs. Their EU-connected research spans two distinct tracks: biomedical nanocarrier science — specifically hemoglobin-based protein nanocarriers that improve tumour oxygenation for more effective photodynamic cancer therapy — and computational analysis of legal texts combining natural language processing with formal reasoning. Both involvements were through researcher mobility schemes, meaning their contribution is joint scientific work and researcher exchange rather than project management. They bring established lab infrastructure and research capacity that European groups can tap as a Latin American scientific node.

What they specialise in

How they've shifted over time

In their first H2020 engagement (2016-2019), UNS participated in MIREL, a project combining natural language processing with formal reasoning over legal texts — a computational rather than experimental science track. By 2019, their EU collaboration had shifted entirely to biomedical materials science: OXIGENATED ran through 2024 and focused on protein nanoparticle design, oxygen delivery, and photodynamic cancer therapy. Whether this reflects a deliberate institutional pivot or two separate research groups independently pursuing MSCA-RISE opportunities is unclear from available data, but the biomedical direction represents their most recent and sustained EU-facing activity.

Their trajectory points toward biomedical materials science and oncology — organisations working on drug delivery systems, nanoparticle chemistry, or photodynamic therapy would find a natural and experienced research counterpart in UNS.

How they like to work

UNS has participated exclusively as a third-party partner in MSCA-RISE projects, which are staff exchange schemes rather than research grants — their value lies in researcher mobility and joint scientific work, not project leadership or budget management. With 22 unique partners across 16 countries from just two projects, they clearly join large multi-institution networks, signalling an open and internationally connected research culture. This pattern suggests they are a willing and experienced collaboration partner, but organisations seeking a project coordinator or technical work-package leader should look elsewhere.

UNS has connected with 22 unique consortium partners across 16 countries through only two MSCA-RISE projects — a broad network relative to their limited project count. Their partners are predominantly European institutions, with UNS serving as the Latin American scientific node in both consortia.

What sets them apart

UNS is one of Argentina's established research universities, offering European consortia a credible and well-networked Latin American academic partner for MSCA-RISE staff exchanges. Their documented work in hemoglobin-based nanocarriers for cancer therapy places them in a specialised and clinically relevant research niche within the broader biomedical materials field. For EU projects requiring a non-EU partner with demonstrated biomedical chemistry capacity and prior MSCA-RISE experience, UNS represents a low-risk, scientifically substantive option.

Highlights from their portfolio

• OXIGENATED
  Addresses a specific unmet clinical need — tumour hypoxia limits photodynamic therapy effectiveness, and this project engineered hemoglobin nanocarriers to solve it, running across a five-year horizon with a broad international consortium.
• MIREL
  An unusual interdisciplinary combination of formal legal reasoning and computational text mining, signalling NLP and knowledge representation capability well outside the biomedical domain that defines UNS's more recent EU activity.